Back

Escaping antibody responses to bacteriolytic enzymes Pal and Cpl-1 by epitope scanning and engineering

Harhala, M. A.; Gembara, K.; Rybicka, I.; Kazmierczak, Z.; Miernikiewicz, P.; Majewska, J.; Budziar, W.; Nasulewicz-Goldeman, A.; Nelson, D. C.; Owczarek, B.; Dabrowska, K.

2022-10-10 bioengineering
10.1101/2022.10.06.511193 bioRxiv
Show abstract

Bacteriolytic enzymes are promising antibacterial agents, but they can cause a typical immune response in vivo. In this study, we used a targeted modification of two antibacterial endolysins, Pal and Cpl-1. We identified the key immunogenic amino-acids, and designed and tested new, bacteriolytic variants with altered immunogenicity. One new variant of Pal (257-259 MKS [->] TFG) demonstrated decreased immunogenicity while a similar mutant (257-259 MKS [->] TFK) demonstrated increased immunogenicity. A third variant (280-282 DKP [->] GGA) demonstrated significantly increased antibacterial activity and it was not cross-neutralized by antibodies induced by the wild-type enzyme. We propose this variant as a new engineered endolysin with increased antibacterial activity that is capable of escaping cross-neutralization by antibodies induced by wild-type Pal. We show that efficient antibacterial enzymes that avoid cross-neutralization by IgG can be developed by epitope scanning, in silico modelling, and substitutions of identified key amino acids with a high rate of success. Importantly, this universal approach can be applied to many proteins beyond endolysins and has the potential for design of numerous biological drugs.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.